CDC37

XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited. This is mainly due to the complexity in their formulation and lack of sufficient pharmacological and safety-related data. To address this gap, a new issue of the Journal of Pharmaceutical Analysis presents three independent studies which assessed the potency of TCM-based compounds for various human diseases, along with their molecular mechanisms of action. Continue Reading Latest research unveils the potential of Traditional Chinese Medicine compounds for the treatment of human diseases The accumulation of excess fat in the liver leads to non-alcoholic fatty liver disease (NAFLD). Oridonin (ORI), a TCM derived from the Chinese herb Rabdosia rubescens, exhibits anti-inflammatory effects. An article available online on 21 August 2023 and published in Volume 13, Issue 11 of the journal in November 2023, now reveals that ORI regulates lipid homeostasis in the liver by maintaining the balance between triglyceride (TG) and phosphatidylethanolamine (PE), through modulation of adipose triglyceride lipase (ATGL) and ethanolamine phosphotransferase 1 (EPT1) expression via the liver X receptor alpha (LXRα) signaling pathway. "When the TG-PE lipid balance is disturbed, the seesaw tilts towards TG, increasing the risk of NAFLD. Restoring lipid homeostasis using compounds like oridonin can alleviate lipid accumulation and liver cytotoxicity," explains Professor Lan Tang. Tumor heterogeneity compromises the efficacy of radiotherapy for treating lung cancer. Radiosensitizers help prime tumor cells and improve their response to radiation. Now, in an article available online on 7 June 2023 and published in Volume 13, Issue 11 of the journal in November 2023, researchers found that ginsenoside Rg5 induced cell-cycle arrest and enhanced radiation-induced cell death. Ginsenoside Rg5 interacts with heat shock protein alpha (HSP90α) with high affinity and reduces the binding between HSP90 and cell division cycle 37 (CDC37), promoting HSP90-CDC37 client protein degradation. "Ginsenoside Rg5 can be potentially developed into a new drug for improving the sensitivity of lung cancer and other types of tumors to radiation therapy," the authors explain. Diabetic retinopathy (DR) is characterized by the activation of oxidative stress pathways in response to high glucose. In a study available online on 12 May 2023 and published in Volume 13, Issue 11 of the journal in November 2023, researchers synthesized a polymeric drug complex by combining a natural flavonoid antioxidant known as dihydromyricetin (DMY) with iron (Fe) ions in nano-coordinated polymer particles (NCPs). Fe-DMY NCPs can alleviate glucose-induced oxidative damage and reverse the pathological features of DR by decreasing the expression of key proteins involved in microvascular dysfunction. Fe-DMY NCPs could also inhibit the activation of Poldip2-Nox4-H2O2 signaling pathway and down-regulate important vascular function indicators such as VCAM-1, HIF-1α, and VEGF. Explaining its applications, the authors say, "We report for the first time the synthesis and validation of ultra-small Fe-DMY NCPs. Fe-DMY complexes bear the potential to alleviate the impact of DR on vision, thus improving the quality of life of affected individuals." These studies provide a scientific basis for the development of TCM-based compounds into effective targeted therapies for various diseases. Reference Titles of original papers: Oridonin restores hepatic lipid homeostasis in an LXRa-ATGL/EPT1 axis-dependent manner Ginsenoside Rg5 enhances the radiosensitivity of lung adenocarcinoma via reducing HSP90-CDC37 interaction and promoting client protein degradation Nanoscale coordination polymer Fe-DMY downregulating Poldip2-Nox4-H2O2 pathway and alleviating diabetic retinopathy Journal name: Journal of Pharmaceutical Analysis DOI: Media contact Mengjie Wang [email protected] Xi'an, China +86-(0)29-88960092 SOURCE Journal of Pharmaceutical Analysis

SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Today, Cardea Bio, Inc. reaches an 8-year milestone of the first external partner starting to use the BPU (Biosignal Processing Unit) platform for advancing drug discovery research to produce new and highly sought-after insights. Continue Reading Dr. Nir Qvit, Bar-Ilan University. Principal Investigator at Bar-Ilan University, Dr. Nir Qvit, shares, "It's kind of a love story between Cardea and my research, as I have already published five papers using the BPU platform. In my estimation, the BPU platform is a very important tool for drug discovery, because it's fast, easy to use, and doesn't require a lot of reagents. For example, the JoVE paper we published in March of 2022 compared a BPU assay with Isothermal Titration Calorimetry (ITC), a common biophysical measurement system. It took one day to gather the data with the BPU versus fourteen days to take the data for ITC with significantly more protein required. This exemplifies how the BPU should be an important part of the toolbox in drug discovery and a technology that all pharma companies can benefit from." While working as a postdoc at Stanford University in the Mochly-Rosen Lab, Dr. Nir Qvit's work caught the attention of Cardea's Chief Technological Officer, Brett Goldsmith, PhD, who initiated a collaboration. The partnership has continued after the Bar-Ilan University offered Dr. Qvit his own lab, focusing on chemistry and biology of protein-protein interactions for drug discovery in pharmacology. "When I learned that Dr. Qvit required in vitro proof that his peptides were binding to specific proteins, I immediately thought that this was something that we should be able to solve with our graphene Field Effect Transistor - the BPU. After attending a conference in San Francisco in January of 2015, I swung by the lab in the afternoon, before having to catch a return flight to San Diego three hours later. Nir and I tried out his biochemistry, honestly expecting that we'd just show some promise and work through refining the measurements over the next few weeks. Amazed by the great results from these very first experiments, I kept rescheduling my flight so we could run more measurements. And in the end, we captured all the measurements that closed the gap on what Nir was missing for his publication that afternoon! So even though I got home almost a day later than planned, it was a breakthrough for us and absolutely worth it," says Dr. Brett Goldsmith, CTO at Cardea Bio. "My eureka moment came after Dr. Goldsmith visited our lab and we had success on the very first day of experimenting. By the end, we had achieved the exact high value results that I could not achieve with any other technology." states Dr. Qvit, and continues, "Initially we were using the BPU platform to see binding interactions between known proteins and peptides that we designed and synthesized. Today we're also doing competitive studies to see if our peptides can inhibit protein-protein interactions. I can't wait to continue to evolve the system to accomplish cell-based assays. With Cardea, I believe the possibilities to solve some of the largest problems in drug discovery are achievable. "When I got my own lab at Bar-Ilan University in 2017, I immediately got the single-BPU Agile R100 device which just recently was upgraded to the new Gateway Reader that runs experiments on eight different BPUs at the same time. I've been impressed with how responsive Cardea has been to our needs, and in turn how they have continuously improved their platform with a rapidly expanding suite of capabilities - improved software interfaces, automated analysis, and the high quality and consistency of the BPU performance." concludes Dr. Nir Qvit of the Bar-Ilan University. Examples of Nit Qvit publications highlighting Cardea's BPU platform Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology - published in the Journal of Visualized Experiments (JoVE) in March 2022 Selective Phosphorylation Inhibitor of Delta Protein Kinase C–Pyruvate Dehydrogenase Kinase Protein–Protein Interactions: Application for Myocardial Injury in Vivo - published by Journal of the American Chemical Society (JACS) in May 2016 About the Nir Qvit Lab at Bar-Ilan Protein-protein interactions represent a significant proportion of functionally relevant biological interactions, and therefore, manipulating these interactions is an important therapeutic strategy. The main focus of the Qvit lab is the identification of molecular modulators of protein-protein interaction using bioinformatics analysis, peptide and protein chemistry, as well as system-wide biological assays. The lab goal is the development of compounds capable of modulating protein complexes that will allow a better understanding of the role of specific protein-protein interactions in cells and will be a starting point for the development of therapeutic compounds. Learn more at ­ About Cardea Bio Cardea Bio is the world's only mass producer of a biocompatible semiconductor, the BPU™ (Biosignal Processing Unit) Platform. The BPU is the first and only graphene semiconductor capable of translating real-time streams of biology's multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea's rapidly expanding IP portfolio now has 33 broad patents issued and another 34 patents pending, cementing Cardea's market-leader position in the graphene biosensor industry, where they are bringing the BPU™ (Biosignal Processing Unit) Platform to market. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor graphene biosensor platform for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. Contact Cardea Lasse Görlitz, VP of Communications US phone: +1 858 319 7135 EU phone: +45 2758 2601 [email protected] SOURCE Cardea Bio